BioAge Labs, Inc.
BioAge Labs, Inc. is listed today as BioAge Labs, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2024 | $194 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
BioAge Labs, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).
SEC Form D · Feb 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2024
That is all the official record says: BioAge Labs, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of BioAge Labs, Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Cormorant Private Healthcare Fund IV LP | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Cormorant Private Healthcare Fund V LP | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 32 investors.
Largest shareholders today
Institutions holding BioAge Labs, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$25 M7.71%
- a16z Capital Management, L.L.C.$23 M7.04%
- Sofinnova Investments, Inc.$16 M4.99%
- Cormorant Asset Management, LP$16 M4.88%
- MPM Bioimpact LLC$13 M4.04%
- Vanguard Capital Management LLC$11 M3.53%
- State Street Corp$10 M2.93%
- Octagon Capital Advisors LP$9 M2.83%
- D. E. Shaw & Co., Inc.$8 M2.52%
- Polar Capital Holdings Plc$8 M2.33%
- Braidwell LP$7 M2.25%
- Geode Capital Management, LLC$7 M2.01%
- Sands Capital Alternatives, LLC$6 M1.71%
- Jpmorgan Chase & Co$6 M1.70%
- Orbimed Advisors LLC$5 M1.55%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dov Goldstein | Executive officer | Feb 2024 |
| Kristen Fortney | Executive officer | Feb 2024 |
| Eric Morgen | Director | Feb 2024 |
| James Healy | Director | Feb 2024 |
| Jason Coloma | Director | Feb 2024 |
| Kristen Fortney | Director | Feb 2024 |
| Patrick Enright | Director | Feb 2024 |
| Rehka Hemrajani | Director | Feb 2024 |
| Vijay Pande | Director | Feb 2024 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.